Two years after the EpiPen price-hike scandal, the Food and Drug Administration has approved a generic competitor by Teva.

Teva’s injector is the first generic competition for Mylan’s EpiPen. Mylan introduced its own generic version of EpiPen in 2016 at half the price. Other non-generic competitors include Adamis Pharmaceuticals’ Symjepi, Impax Pharmaceuticals’ AdrenaClick, and Kaleo’s Auvi-Q.

Mylan has also been struggling with EpiPen shortages in recent months due to manufacturing delays, leaving some parents scrambling as their children head back to school without their needed EpiPen.

In August 2016, Mylan came under fire for the price of EpiPen, which increased 400% over a decade. CEO Heather Bresch later defended the price because the company had invested more than $1 billion in improving the product and increasing access. Bresch later testified before Congress and the company settled a Justice Department probe for $465 million.

Last year, the FDA issued a guidance making it easier for generic companies to get drug-device combinations approved. EpiPen generics fell into that category because the injection is both a drug (epinephrine) and a device (the auto injector).

More generic approvals are part of the Trump administration’s plans to increase competition and lower drug prices.